All In Biotech

Drug Trial Radar · NCT00712933

A Continuation Trial for Subjects With Lupus That Completed Protocol HGS1006-C1056 or HGS1006-C1057

A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™)a Fully Human Monoclonal Anti-BLyS Antibody in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 or HGS1006-C1057

Last checked: Nov 20, 2026Latest source record: Dec 5, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

738

Actual

Start

May 30, 2008

Primary completion

Dec 9, 2016

Study completion Dec 9, 2016

Sponsor

Sponsor type
Industry
Collaborators
GlaxoSmithKline
First posted
Jul 10, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a long-term continuation study to provide continuing treatment to subjects with SLE.

Conditions

  • Systemic Lupus Erythematosus

Interventions

  • belimumabDrug

    Recombinant, fully human, monoclonal antibody Comparison of the 1 mg/kg and 10 mg/kg dose of belimumab given IV every 28 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse Events (AE)Time frame: Up to 9 years
  2. AE Rates by System Organ Class (SOC) During the StudyTime frame: Up to 9 years
  3. Number of Participants With Serious Adverse Events (SAE)Time frame: Up to 9 years
  4. SAE Rates by SOC During the StudyTime frame: Up to 9 years
  5. Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time PointsTime frame: Baseline and up to 9 years
  6. Change From Baseline in Platelets (Plt), Lymphocytes (Lymp), Leukocytes (Leu), Eosinophils (Eos), Basophils (Baso), Monocytes (Mono), Neutrophils (Neu), Neutrophils Band Form (NeuBF), Neutrophils Segmented (NeuS) at the Indicated Time PointsTime frame: Baseline and up to 9 years
  7. Change From Baseline in Hemoglobin (Hg) at the Indicated Time PointsTime frame: Baseline and up to 9 years
  8. Change From Baseline in Hematocrit at the Indicated Time PointsTime frame: Baseline and up to 9 years
  9. Change From Baseline in Erythrocytes (Eryth) at the Indicated Time PointsTime frame: Baseline and up to 9 years
  10. Change From Baseline in Calcium (Ca), Carbon Dioxide (CO2), Chloride, Magnesium (Mg), Phosphate (Phos), Potassium (K), Sodium (Na) at the Indicated Time PointsTime frame: Baseline and up to 9 years
  11. Change From Baseline in Blood Urea Nitrogen/Creatinine (BUN/Cr) at the Indicated Time PointsTime frame: Baseline and up to 9 years
  12. Change From Baseline in Albumin (Alb) and Protein (Pro) at the Indicated Time PointsTime frame: Baseline and up to 9 years
  13. Change From Baseline in BUN and Glucose at the Indicated Time PointsTime frame: Baseline and up to 9 years
  14. Change From Baseline in Creatinine (Cr) and Urate at the Indicated Time PointsTime frame: Baseline and up to 9 years
  15. Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase (GGT) and Lactate Dehydrogenase (LDH) LevelsTime frame: Baseline and up to 9 years
  16. Change From Baseline in Bilirubin (Bili) LevelsTime frame: Baseline and up to 9 years
  17. Change From Baseline in Immunoglobulin G (IgG) LevelsTime frame: Baseline and up to 9 years
  18. Number of Participants With Immunogenic Response by YearTime frame: Up to 9 years
  19. Number of Participants With IgG Values Below the Lower Limit of Normal by YearTime frame: Up to 9 years
  20. Number of Participants With Shifts From Baseline in Prednisone and Other Steroids Dose by VisitTime frame: Up to 9 years
  21. Number of Participants With Any SLICC/ ACR Damage Index Worsening (Change > 0) From Baseline by VisitTime frame: Up to 9 years

Locations

110 sites in 28 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Buenos Aires, Argentina

  • GSK Investigational Site

    Buenos Aires, Argentina

  • GSK Investigational Site

    Ciudad Autonoma Buenos Aires, Argentina

  • GSK Investigational Site

    Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina

  • GSK Investigational Site

    Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina

  • GSK Investigational Site

    La Plata, Buenos Aires, Argentina

  • GSK Investigational Site

    Rosario, Santa Fe Province, Argentina

  • GSK Investigational Site

    San Miguel de Tucumán, Tucumán Province, Argentina

  • GSK Investigational Site

    Vienna, Austria

  • GSK Investigational Site

    Liège, Belgium

  • GSK Investigational Site

    Campinas, Brazil

  • GSK Investigational Site

    Rio de Janeiro, Brazil

  • GSK Investigational Site

    São Paulo, Brazil

  • GSK Investigational Site

    São Paulo, Brazil

  • GSK Investigational Site

    Salvador, Estado de Bahia, Brazil

  • GSK Investigational Site

    Goiânia, Goiás, Brazil

  • GSK Investigational Site

    Juiz de Fora, Minas Gerais, Brazil

  • GSK Investigational Site

    Recife, Pernambuco, Brazil

  • GSK Investigational Site

    Porto Alegre, Rio Grande do Sul, Brazil

  • GSK Investigational Site

    São Paulo, São Paulo, Brazil

  • GSK Investigational Site

    Toronto, Ontario, Canada

  • GSK Investigational Site

    Montreal, Quebec, Canada

  • GSK Investigational Site

    Santiago, Chile

  • GSK Investigational Site

    Viña del Mar, Valparaiso, Chile

  • GSK Investigational Site

    Barranquilla, Colombia

  • GSK Investigational Site

    Bogotá, Colombia

  • GSK Investigational Site

    Bucaramanga, Colombia

  • GSK Investigational Site

    Medellín, Colombia

  • GSK Investigational Site

    Brno-Bohunice, Czechia

  • GSK Investigational Site

    Hradec Králové, Czechia

  • GSK Investigational Site

    Olomouc, Czechia

  • GSK Investigational Site

    Prague, Czechia

  • GSK Investigational Site

    Suresnes, France

  • GSK Investigational Site

    Berlin, Germany

  • GSK Investigational Site

    Berlin, Germany

  • GSK Investigational Site

    Kiel, Germany

  • GSK Investigational Site

    Freiburg im Breisgau, Baden-Wurttemberg, Germany

  • GSK Investigational Site

    Erlangen, Bavaria, Germany

  • GSK Investigational Site

    Frankfurt am Main, Hesse, Germany

  • GSK Investigational Site

    Hanover, Lower Saxony, Germany

Showing 40 of 110 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.